Skip to main content
    M

    Mediwound Ltd (MDWD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $13.55
    +0.65 (+5.04%)

    Market Cap: $185.63M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Mediwound Ltd (MDWD) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Mediwound (MDWD) is expected to report earnings on Mar 3, 2027. In the quarter ended Sep 30, 2026, Mediwound reported EPS of -$0.65, above the -$0.66 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    56%(22/39)
    Avg Surprise
    +3.84%
    Streak
    1 Q

    Upcoming Estimates

    Reports Mar 3, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.65
    Range-$0.77 - -$0.55
    8 analysts
    Revenue Consensus
    $12.00M
    Range$4.31M - $16.70M
    8 analysts
    Reports May 25, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.64
    Range-$0.72 - -$0.55
    4 analysts
    EPS Revisions
    0
    2
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.62-3.2%
    60d ago-$0.62-3.2%
    30d ago-$0.62-3.2%
    7d ago-$0.62-3.2%
    Current-$0.64
    Revenue Consensus
    $7.32M
    Range$6.66M - $8.50M
    5 analysts

    Next Report

    MDWD has an expected report date of Mar 3, 2027.

    MDWD Earnings Call

    The latest MDWD earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, MDWD beat 22, missed 16 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $3.57M, down 34.3% from $5.43M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.65-$0.66-$0.92 - -$0.62+1.52%BeatN/A52 up, 3 downNov 12, 2026$3.57M
    Jun 30, 2026-$0.77-$0.76-$0.91 - -$0.68-1.32%MissN/A51 up, 2 downAug 13, 2026$3.09M
    Mar 31, 2026-$0.23-$0.66-$0.73 - -$0.62+65.15%BeatN/A51 up, 2 downMay 27, 2026$1.48M
    Dec 31, 2025-$0.56-$0.61-$0.77 - -$0.39+8.20%BeatN/A50 up, 3 downMar 5, 2026$1.87M
    Sep 30, 2025-$0.24-$0.83-$1.38 - -$0.60+71.08%BeatN/A51 up, 3 downNov 20, 2025$5.43M
    Jun 30, 2025-$1.23-$0.57-$0.70 - -$0.30-115.79%MissN/A53 up, 1 downAug 14, 2025$5.71M
    Mar 31, 2025-$0.07-$0.66-$0.73 - -$0.61+89.39%BeatN/A5N/AMay 21, 2025$3.96M
    Dec 31, 2024-$0.36-$0.59-$0.74 - -$0.52+38.98%BeatN/A41 up, 2 downMar 19, 2025$5.84M
    Sep 30, 2024-$0.98-$0.44-$0.49 - -$0.38-122.73%MissN/A32 up, 0 downNov 26, 2024$4.36M
    Jun 30, 2024-$0.68-$0.42-$0.48 - -$0.39-61.90%Miss-780.0%41 up, 0 downAug 14, 2024$5.06M
    Mar 31, 2024-$1.05-$0.41-$0.44 - -$0.35-156.10%MissN/A30 up, 0 downMay 29, 2024$4.96M
    Dec 31, 2023-$0.19-$0.23-$0.40 - $0.07+17.39%BeatN/A40 up, 0 downMar 21, 2024$5.34M
    Sep 30, 2023-$0.24-$0.39-$0.57 - -$0.36+38.46%BeatN/A40 up, 0 downNov 21, 2023$4.78M
    Jun 30, 2023$0.10-$0.34-$0.52 - -$0.26+129.41%BeatN/A30 up, 0 downAug 15, 2023$4.77M
    Mar 31, 2023-$0.44-$0.43-$0.68 - $0.32-2.33%MissN/A41 up, 0 downMay 30, 2023$3.80M
    Dec 31, 2022-$1.18-$0.59-$0.70 - -$0.38-100.00%MissN/A30 up, 0 downMar 16, 2023$11.62M
    Sep 30, 2022-$0.91-$0.68-$0.77 - -$0.56-33.82%MissN/A40 up, 0 downNov 15, 2022$5.80M
    Jun 30, 2022-$0.91-$0.68-$0.84 - -$0.56-33.82%MissN/A60 up, 0 downAug 9, 2022$4.67M
    Mar 31, 2022-$0.84-$0.76-$0.98 - -$0.42-10.53%MissN/A50 up, 0 downMay 17, 2022$4.41M
    Dec 31, 2021-$1.05-$1.05-$1.19 - -$0.910.00%In lineN/A60 up, 0 downMar 17, 2022$5.49M
    Sep 30, 2021-$0.84-$0.90-$1.05 - -$0.77+6.67%BeatN/A6N/ANov 16, 2021$6.37M
    Jun 30, 2021-$0.84-$0.78-$0.98 - $0.91-7.69%MissN/A6N/AAug 10, 2021$6.06M
    Mar 31, 2021-$0.70-$0.81-$1.05 - -$0.42+13.58%BeatN/A6N/AMay 5, 2021$5.85M
    Dec 31, 2020-$0.42-$0.79-$0.98 - -$0.49+46.84%BeatN/A5N/AFeb 25, 2021$6.67M
    Sep 30, 2020-$0.49-$0.67-$0.91 - -$0.42+26.87%BeatN/A5N/ANov 10, 2020$6.63M
    Jun 30, 2020-$0.77-$0.84-$0.98 - -$0.70+8.33%Beat-123.4%4N/AAug 6, 2020$4.03M
    Mar 31, 2020-$0.63-$1.00-$1.19 - -$0.91+37.00%BeatN/A4N/AMay 20, 2020$4.44M
    Dec 31, 2019-$0.91-$0.73-$1.19 - -$0.21-24.66%MissN/A5N/AFeb 25, 2020$5.44M
    Sep 30, 2019-$0.77-$0.91-$1.33 - -$0.77+15.38%BeatN/A5N/ANov 14, 2019$5.14M
    Jun 30, 2019$3.29-$0.18-$1.19 - $3.36N/AN/AN/A5N/AAug 13, 2019$20.75M
    Mar 31, 2019-$1.05-$0.98-$1.05 - -$0.84-7.14%MissN/A4N/AMay 21, 2019$461000
    Dec 31, 2018-$0.35-$1.06-$1.33 - -$0.91+66.98%BeatN/A5N/AMar 25, 2019$992000
    Sep 30, 2018-$0.77-$1.37N/A+43.80%BeatN/AN/AN/ANov 13, 2018$858000
    Jun 30, 2018-$1.05-$1.37-$2.03 - -$0.91+23.36%BeatN/A5N/AAug 7, 2018$1.03M
    Mar 31, 2018-$1.19-$0.94-$1.75 - -$0.84-26.60%MissN/A5N/AMay 10, 2018$520000
    Dec 31, 2017-$0.63-$1.19-$1.47 - -$0.98+47.06%BeatN/A5N/AMar 19, 2018$530000
    Sep 30, 2017-$1.12-$1.33-$1.40 - -$1.19+15.79%BeatN/A5N/ANov 16, 2017$739000
    Jun 30, 2017-$1.40-$1.37-$1.61 - -$0.91-2.19%MissN/A5N/AAug 3, 2017$687000
    Mar 31, 2017-$1.40-$1.18N/A-18.64%MissN/AN/AN/AMay 8, 2017$540000
    Dec 31, 2016-$0.63-$1.74N/A+63.79%BeatN/AN/AN/AFeb 21, 2017$430000
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$2.10, after -$3.07 the year before. It was -$6.02 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$2.10N/A
    Dec 31, 2024-$3.07N/A
    Dec 31, 2023-$0.77N/A
    Dec 31, 2022-$3.84N/A
    Dec 31, 2021-$3.43N/A
    Dec 31, 2020-$2.31-512.5%
    Dec 31, 2019$0.56N/A
    Dec 31, 2018-$3.36N/A
    Dec 31, 2017-$4.55N/A
    Dec 31, 2016-$6.02N/A

    Earnings Calls

    The 7 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,000 words across 9 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,0219
    2026Q2Jun 30, 20265,24711
    2026Q1Mar 31, 20264,62711
    2025Q4Dec 31, 20255,23911
    2025Q3Sep 30, 20254,0099
    2025Q2Jun 30, 20254,58510
    2025Q1Mar 31, 20254,1529

    2026Q3 Earnings Call

    Opening remarks

    Gaia Vasiliver-Shamis Lifesci Advisors Representative Thank you, Sagar, and welcome, everyone. Earlier today, before the market opened, MediWound issued a press release announcing financial results for the third quarter ended September 30, 2026. You may access this press release on the company's website under the Investors tab. I would ask you to review the full text of our forward-looking statements within this morning's press release. Before we begin, I would like to remind everyone that statements made during this call, including the Q&A session, relating to MediWound's expected future performance, future business prospects, or future events or plans are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. These statements may involve risks and uncertainties that could cause actual results to differ materially from expectations and are described more fully in our filings with the SEC. In addition, all forward-looking statements represent our view only as of today, and MediWound assumes no obligation to update or supplement any forward-looking statements, whether as a result of new information, future events, or otherwise. This conference call is the property of MediWound, and any recording or rebroadcast is expressly prohibited without the written consent of MediWound. With us today are Ofer Gonen, Chief Executive Officer of MediWound; Hani Luxenburg, Chief Financial Officer; and Barry Wolfenson, Executive Vice President of Strategy and Corporate Development. Following our prepared remarks, we will open the call for Q&A. Now I would like to turn the call over to Ofer Gonen, Chief Executive Officer of MediWound. Ofer?

    Ofer Gonen CEO Thank you, Gaia, and good morning, everyone. During the third quarter, we advanced EscharEx development, supported NexoBrid's commercial growth and government program, and continued preparing our expanded manufacturing facility to meet future demand. Let me start with an update on EscharEx. The global Phase III VALUE trial in venous leg ulcers remains our top priority. Enrollment continues, and we remain on track to complete the prespecified interim sample size reassessment and enrollment by the end of the first quarter of 2027. The current enrollment target is 216 patients across approximately 40 sites in the United States, Europe, and Israel. During the quarter, the Independent Data and Safety Monitoring Board completed its prespecified periodic review of the VALUE trial, identified no safety concerns, and recommended that the trial continue as planned without modifications. The next DSMB meeting is scheduled for early January 2027. The following meeting is expected at the end of the first quarter of 2027, at which the DSMB will also conduct the interim sample size reassessment. Beyond venous leg ulcers, we continue to advance toward clinical trials in diabetic foot ulcers and pressure ulcers.

    Frequently Asked Questions About MDWD

    When is Mediwound's next earnings date?

    Mediwound's next earnings report is expected for Mar 3, 2027.

    Did MDWD beat earnings estimates last quarter?

    Yes. Mediwound reported EPS of -$0.65 for the quarter ended Sep 30, 2026, above the -$0.66 estimate, a 1.52% surprise.

    What EPS do analysts expect from MDWD next quarter?

    The consensus EPS estimate for Mediwound for the quarter ending Dec 31, 2026 is -$0.65 from 8 analysts, with estimates from -$0.77 to -$0.55.

    How often does MDWD beat earnings estimates?

    Mediwound beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +19.65%.